Circle Pharma Announces Preclinical Data Poster Presentation of CID-078, a First-and-Only-in-Class Cyclin A/B RxL Inhibitor at the 2024 World Conference on Lung Cancer Download PDF ...

Press Release Circle Pharma announced today that two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting held April 14-19, in Orlando, Florida, highlight ...

The full poster is available here.. About CID-078, Circle Pharma’s Cyclin A/B RxL Inhibitor Program . CID-078 is an orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory ...

SOUTH SAN FRANCISCO, Calif., May 27, 2025--Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation ...